NEC-HM414-100μg / 询价
NEC-HM414-500μg / 询价
NEC-HM414-500μgx2 / 询价
Human Nectin-4 Protein IgV Domain
Recombinant Human Nectin-4 Protein IgV Domain is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Gly32-Leu146 [Accession | Q96NY8-1].
The protein has a predicted MW of 15.8 kDa. Due to glycosylation, the protein migrates to 16-20 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human Nectin-4 IgV Domain on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human Nectin-4 IgV Domain is greater than 95% as determined by SEC-HPLC.
Immobilized Human Nectin-4 IgV Domain, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Anti-Nectin-4 Antibody, hFc Tag with the EC50 of 3.0ng/ml determined by ELISA.
Nectin-4 seems to be involved in cell adhesion through trans-homophilic and -heterophilic interactions, the latter including specifically interactions with NECTIN1. Does not act as receptor for alpha-herpesvirus entry into cells.(Microbial infection) Acts as a receptor for measles virus.
EDSS1; LNIR; Nectin4; PRR4; NECTIN4; PVRL4
(1) Challita-Eid P M , Satpayev D , Yang P , et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models[J]. Cancer Research, 2016:0008-5472.CAN-15-1313.
